Table 2.
Baseline characteristics of patients in UK Clinical Practice Research Datalink database with individual components of primary study composite endpoint of hypertension, incident heart failure, and all cause mortality (cases) and matched controls. Figures are numbers (percentage) of patients unless stated otherwise
| Cases (n=61 072) | Controls (n=61 072) | P value | |
|---|---|---|---|
| Mean (SD) age (years) | 69 (12.3) | 69 (12.4) | — |
| Men | 25 281 (41) | 25 281 (41) | — |
| BMI: | |||
| <18.5 | 886 (2) | 782 (1) | <0.01 |
| 18.5-24.9 | 15 287 (25) | 15 354 (25) | |
| 25-29.9 | 17 618 (29) | 17 536 (29) | |
| ≥30 | 10 611 (17) | 9904 (16) | |
| Missing | 16 670 (27) | 17 496 (22) | — |
| Smoking status: | |||
| None | 8120 (13) | 9732 (16) | <0.01 |
| Current smoker | 11 288 (19) | 8597 (14) | |
| Ex-smoker | 26 685 (44) | 29 068 (48) | |
| Missing | 14 979 (25) | 16375 (22) | — |
| Disease history: | |||
| Angina | 11 653 (19) | 7373 (12) | <0.01 |
| Heart failure | 4606 (8) | 3373 (6) | <0.01 |
| Peripheral vascular disease | 2507 (4) | 1470 (2) | <0.01 |
| Migraine | 3188 (5) | 2764 (5) | <0.01 |
| Oesophageal disease | 136 (0.22) | 108 (0.2) | 0.06 |
| Diabetes | 9485 (16) | 6848 (11) | <0.01 |
| Chronic kidney disease | 5234 (89) | 4672 (7) | <0.01 |
| COPD | 6113 (10) | 5325 (9) | <0.01 |
| Drug history: | |||
| Cardiovascular disease drugs | 44 957 (74) | 35 497 (58) | <0.01 |
| ACE/ARB | 21 666 (36) | 17 183 (28) | <0.01 |
| Proton pump inhibitors | 22 381 (37) | 20 562(34) | <0.01 |
| Potassium | 2811 (5) | 2154 (4) | <0.01 |
| Antipsychotic | 16 784 (28) | 14 932 (25) | <0.01 |
| HIV | 3 (0) | 1 (0) | <0.01 |
| Steroids | 4486 (7) | 3924 (6) | <0.01 |
| NSAIDs | 40 940 (67) | 42 299 (69) | <0.01 |
BMI=body mass index; COPD=chronic obstructive pulmonary disease; ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin receptor blockers; NSAIDs=non-steroidal anti-inflammatories.